The results of a five-year, multi-center clinical trial testing an innovative combination of an adenovirus and an immune checkpoint inhibitor against recurrent glioblastoma were published this week in Nature Medicine. The Phase 1/2 trial was conducted at multiple sites around the United States, including at NewYork-Presbyterian Weill Cornell Medicine, where Dr. Rohan Ramakrishna was the principal investigator. The trial, the first of its kind in humans, showed the...